Leading psychedelic therapy training company to host expert discussion on landmark ruling’s implications for PTSD treatment.
MEDIA CONTACT:
Brad Burge
brad@fluencetraining.com
1-650-863-6887
New York, New York — Fluence, a pioneer in psychedelic therapy education, today announced a free webinar titled “MDMA Decision Debrief” to discuss the FDA’s forthcoming decision on MDMA-assisted therapy (MDMA-AT) for PTSD. The webinar, scheduled for August 13, 2024, from 4:00 PM to 5:00 PM ET, will feature Fluence co-founders Dr. Ingmar Gorman and Dr. Elizabeth Nielson, who also served as site co-principal investigators and study therapists on the MAPS clinical trials examining MDMA’s efficacy for PTSD.
With the FDA’s decision expected by August 12, this timely webinar will provide comprehensive insights into its implications for patients, healthcare providers, and the mental health industry. The event will start with a 40-minute discussion led by Drs. Gorman and Nielson, followed by a live Q&A session on Zoom.
“As both researchers and educators in the field of psychedelic-assisted therapy, we’re uniquely positioned to unpack the FDA’s decision and its far-reaching consequences,” said Dr. Elizabeth Nielson, “This webinar aims to provide clarity and context for this potentially groundbreaking moment in mental health treatment.”
Key topics to be covered include:
- Overview of the FDA’s decision and the drug approval process
- Examination of clinical trials and research evidence supporting MDMA-AT for PTSD
- Practical advice for clinicians on discussing MDMA-AT availability with patients
- Regulatory, ethical, and logistical considerations of implementing MDMA-AT
- Future perspectives on potential approvals of other psychedelic therapies
“Regardless of the FDA’s decision, this moment marks a significant milestone in the field of psychedelic medicine,” added Dr. Ingmar Gorman. “Our goal is to ensure that mental health professionals and interested individuals have a clear understanding of what this means for the future of PTSD treatment.”
The webinar is open to mental health professionals, researchers, and anyone with a personal or professional interest in MDMA and PTSD treatment. All attendees will receive free access to Fluence’s on-demand “Introduction to MDMA-assisted Therapy Research” course.
While live attendance is encouraged, a recording will be available for those unable to join in real-time.
About Fluence
Fluence is the global leader in providing comprehensive, evidence-based training in psychedelic therapy and integration to healthcare professionals. With a mission to equip clinicians with the clinical skills and knowledge necessary for effective, evidence-based psychedelic therapy and integration services, Fluence offers ethical, dynamic, interactive training both online and in-person. Since its inception, Fluence has educated over 7,000 practitioners, establishing itself as a frontrunner in psychedelic therapy training for private enterprises and research organizations.